Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$30.95 USD
+1.11 (3.72%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $30.96 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.95 USD
+1.11 (3.72%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $30.96 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $45.73, moving -0.61% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.45, marking a -1.42% move from the previous day.
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%
by Zacks Equity Research
Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
by Zacks Equity Research
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $44.46 in the latest trading session, marking a -0.34% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $47.17 in the latest trading session, marking a -1.34% move from the prior day.
Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $50.16 in the latest trading session, marking a +0.95% move from the prior day.
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $51.08, marking a -0.8% move from the previous day.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD
by Zacks Equity Research
Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.
Cassava Sciences, Inc. (SAVA) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $62.08 in the latest trading session, marking a -0.1% move from the prior day.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
by Zacks Equity Research
Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.